BOK Financial’s Cytokinetics CYTK Stock Holding History

BOK Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12	Closed	-$482	–	1188
2025 Q1	$482	Hold	12	–	–	﹤0.01%	1225
2024 Q4	$559	Buy	+12	New	+$623	﹤0.01%	1237

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BOK Financial's CYTK Position: Q2 2025 in Review

BOK Financial sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 12 shares — an estimated $482 sold.

BOK Financial first reported a position in CYTK in Q4 2024 and held it in 2 quarters. The position peaked at $559 in Q4 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

BOK Financial reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
BOK Financial sold 12 Cytokinetics shares in Q2 2025, an estimated $482.
BOK Financial first reported a position in Cytokinetics in Q4 2024 and held it in 2 quarters.
BOK Financial's Cytokinetics position peaked at $559 in Q4 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on BOK Financial's 13F filing for Q2 2025, filed 12 Aug 2025.